Replies to post #196094 on Biotech Values

[DewDiligence]

ZGNX +134% on phase-3 data in Dravet syndrome:

https://finance.yahoo.com/news/zogenix-announces-positive-top-line-110000801.html

ZX008 is a low-dose formulation of fenfluramine.